Cagrilintide (AM833) | Peptide Reference Material
RESEARCH PEPTIDE

Cagrilintide (AM833) | Peptide Reference Material

Long-Acting Amylin Analogue — Research Peptide
$39.00
Lipidated amylin analogue supplied as a lyophilized laboratory reference material for receptor-pharmacology research. Research use only. Not for human or veterinary use.
✓ Scientific Identity Established
⏳ Laboratory Testing In Progress
⏳ Batch Documentation Pending
✓ Research Use Only
✓ U.S. Fulfillment
In Laboratory Testing
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
1415456-99-3
Purity
≥98%
Molecular Formula
C194H312N54O59S2
Molecular Weight
4409.01
Appearance
White lyophilized powder
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

Cagrilintide (AM833; CAS 1415456-99-3) is a long-acting lipidated amylin analogue. The complete molecular entity comprises a 37-amino-acid amylin-analogue backbone carrying an intramolecular disulfide bridge between its two cysteine residues (the native-amylin-equivalent bridge; backbone positions 2 and 7), a C-terminal amide, and an eicosanedioic acid (C20 fatty diacid) attached through a gamma-glutamyl linker to the N-terminal-region lysine. The lipidation confers albumin binding and the protracted pharmacokinetic profile engineered in its development (Kruse et al., 2021).

As a laboratory reference material, cagrilintide supports research into amylin-receptor pharmacology and lipidated-peptide protraction chemistry. This material is supplied for laboratory research use only.

Primary Research Category
Analytical Sciences
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Receptor Pharmacology Receptor Binding Analytical Chemistry

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

Cagrilintide is an agonist of calcitonin-family G-protein-coupled receptors: pharmacological characterization established agonism at the calcitonin receptor and at RAMP-containing amylin receptor complexes, profiled against selective and nonselective calcitonin-family agonists (Fletcher et al., 2021). These receptor families are distinct from GLP-1 or CGRP receptor pharmacology and are not conflated in this dossier.

Primary Organ Systems
  • Endocrine System
  • Central Nervous System
  • Metabolic System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

In Laboratory Testing
Laboratory Documentation In Progress

Laboratory documentation for the current lot is being completed.

Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Pharmacology Study•Journal of Medicinal Chemistry• 2021

Development of Cagrilintide, a Long-Acting Amylin Analogue

Foundational medicinal-chemistry report describing the design and development of cagrilintide, including the backbone substitutions and the fatty-diacid/gamma-Glu lipidation that confer its long-acting protraction profile.
Velora Research Insight
Molecular-design anchor: establishes the complete conjugate architecture and protraction rationale of the governed identity. Novo Nordisk originating lineage — labeled as the founding, non-independent report.
PubMed →DOI →
Mechanistic Study•The Journal of Pharmacology and Experimental Therapeutics• 2021

AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists

Mechanistic receptor-pharmacology study characterizing AM833 (cagrilintide) as an agonist of calcitonin-family G-protein-coupled receptors, benchmarked against six selective and nonselective agonists.
Velora Research Insight
Independent receptor-level anchor distinguishing calcitonin-receptor and RAMP-containing amylin-receptor-complex agonism — the dossier's receptor-terminology discipline rests here.
PubMed →DOI →
Clinical Trial•The Lancet• 2021

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Randomized, double-blind, placebo- and active-controlled phase 2 dose-finding trial of once-weekly cagrilintide in people with overweight and obesity.
Velora Research Insight
Primary clinical research context for the amylin-analogue pharmacology; cited as scientific context, not as a therapeutic or weight-loss representation of this material.
PubMed →DOI →
Systematic Review•Journal of Diabetes and Metabolic Disorders• 2026

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis

Independent systematic review and meta-analysis synthesizing the cagrilintide (and cagrilintide/semaglutide co-administration) trial literature in overweight and obesity.
Velora Research Insight
Independent evidence synthesis consolidating the clinical research context; independence anchor beyond the originating lineage.
PubMed →DOI →